SIC
NVO

Salem Investment Counselors’s Novo Nordisk NVO Stock Holding History

Salem Investment Counselors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.96M Buy
61,839
+10,634
+21% +$457K 0.07% 143
2026
Q1 		$1.91M Buy
51,205
+41,513
+428% +$1.97M 0.06% 166
2025
Q4 		$493K Sell
9,692
-9,336
-49% -$477K 0.01% 280
2025
Q3 		$1.06M Sell
19,028
-47
-0.2% -$2.75K 0.03% 203
2025
Q2 		$1.32M Sell
19,075
-4,400
-19% -$299K 0.04% 179
2025
Q1 		$1.65M Buy
23,475
+1,549
+7% +$128K 0.06% 156
2024
Q4 		$1.89M Buy
21,926
+491
+2% +$53.1K 0.06% 154
2024
Q3 		$2.55M Buy
21,435
+1,637
+8% +$218K 0.08% 134
2024
Q2 		$2.83M Buy
19,798
+6,338
+47% +$840K 0.09% 125
2024
Q1 		$1.74M Buy
13,460
+11,318
+528% +$1.35M 0.06% 155
2023
Q4 		$222K Hold
2,142
– – 0.01% 338
2023
Q3 		$195K Buy
2,142
+504
+31% +$44.4K 0.01% 340
2023
Q2 		$133K Sell
1,638
-1,040
-39% -$85K ﹤0.01% 374
2023
Q1 		$215K Hold
2,678
– – 0.01% 325
2022
Q4 		$181K Buy
2,678
+2,660
+14,778% +$156K 0.01% 344
2022
Q3 		$1K Hold
18
– – ﹤0.01% 1001
2022
Q2 		$1K Hold
18
– – ﹤0.01% 1032
2022
Q1 		$1K Hold
18
– – ﹤0.01% 970
2021
Q4 		$1K Hold
18
– – ﹤0.01% 1042
2021
Q3 		$1K Hold
18
– – ﹤0.01% 944
2021
Q2 		$1K Hold
18
– – ﹤0.01% 872
2021
Q1 		$1K Hold
18
– – ﹤0.01% 838
2020
Q4 		$1K Buy
+18
New +$622 ﹤0.01% 777
2018
Q3 		– Sell
-2,600
Closed -$60K – 500
2018
Q2 		$60K Hold
2,600
– – 0.01% 276
2018
Q1 		$63K Hold
2,600
– – 0.01% 264
2017
Q4 		$70K Buy
2,600
+1,600
+160% +$40.7K 0.01% 278
2017
Q3 		$24K Sell
1,000
-1,600
-62% -$36.2K ﹤0.01% 382
2017
Q2 		$56K Sell
2,600
-5,450
-68% -$110K 0.01% 302
2017
Q1 		$139K Sell
8,050
-86
-1% -$1.5K 0.01% 264
2016
Q4 		$146K Sell
8,136
-12,564
-61% -$228K 0.02% 253
2016
Q3 		$4.3K Sell
20,700
-3,200
-13% -$79.3K 0.06% 171
2016
Q2 		$643K Hold
23,900
– – 0.08% 161
2016
Q1 		$648K Hold
23,900
– – 0.08% 154
2015
Q4 		$694K Sell
23,900
-2,000
-8% -$55.4K 0.09% 153
2015
Q3 		$696K Buy
25,900
+2,000
+8% +$56.6K 0.09% 153
2015
Q2 		$654K Sell
23,900
-600
-2% -$16.9K 0.08% 165
2015
Q1 		$654K Hold
24,500
– – 0.08% 173
2014
Q4 		$518K Hold
24,500
– – 0.06% 189
2014
Q3 		$583K Hold
24,500
– – 0.07% 180
2014
Q2 		$566K Buy
24,500
+4,000
+20% +$88.3K 0.07% 184
2014
Q1 		$468K Buy
+20,500
New +$437K 0.06% 200

Other funds holding NVO

Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return

Salem Investment Counselors's NVO Position: Q2 2026 in Review

Salem Investment Counselors increased its Novo Nordisk (NVO) stake by 21% in Q2 2026, buying an estimated $457K and bringing the position to 61,839 shares worth $2.96M. The position accounts for 0.07% of the portfolio, ranked #143.

Salem Investment Counselors first reported a position in NVO in Q1 2014 and has held it in 41 quarters since. 604 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Salem Investment Counselors held 61,839 shares of Novo Nordisk worth $2.96M as of Q2 2026.
  • Salem Investment Counselors bought 10,634 Novo Nordisk shares in Q2 2026, an estimated $457K.
  • Novo Nordisk made up 0.07% of Salem Investment Counselors's portfolio in Q2 2026, its #143 holding.
  • Salem Investment Counselors first reported a position in Novo Nordisk in Q1 2014 and has held it in 41 quarters since.
  • 604 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.